BCL2 and acute lymphoblastic leukemia: Human T‐ALL cell lines display a close association between FBXW7 deficiency and MCL1 overexpression and therefore, T‐ALL cell lines with defective or inactive FBXW7 are resistant to Bcl‐2 antagonist ABT‐737 but are sensitive to the multi‐kinase inhibitor, Sorafenib.